Reduced E-cadherin expression is a prognostic biomarker of non-small cell lung cancer: A meta-analysis based on 2395 subjects

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 11, 2014, Pages 4352-4356

  Yan, Bo ^a   Zhang, Wei ^a   Jiang, Li Yan ^a   Qin, Wen Xin ^b   Wang, Xin ^c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI CANCER INSTITUTE   (China)

^c JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

E cadherin; Non small cell lung cancer; Prognosis

Indexed keywords

UVOMORULIN;

ARTICLE; CANCER PROGNOSIS; CANCER SCREENING; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; META ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PUBLISHING; QUALITY CONTROL; SYSTEMATIC REVIEW;

EID: 84918588495     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. O’Connor SJ. Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe. Eur J Cancer 2011; 47 Suppl 3: S346-7.
2. Yen KT, Putzke JD, Staats BA, Burger CD. The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. Respirology 2005; 10: 643-8.
3. Quadrelli S, Lyons G, Colt H, Chimondeguy D, Silva C. Lung cancer as a second primary malignancy: increasing prevalence and its influence on survival. Ann Surg Oncol 2009; 16: 1033-8.
4. Li C, Hong W. Research status and funding trends of lung cancer biomarkers. J Thorac Dis 2013; 5: 698-705.
5. Watanabe Y. TNM classification for lung cancer. Ann Thorac Cardiovasc Surg 2003; 9: 343-50.
6. Ganti AK, West WW, Lackner RP, Kessinger A. Current concepts in the diagnosis and management of small-cell lung cancer. Oncology (Williston Park) 2010; 24: 1034-9.
7. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med 2013; 137: 1286-95.
8. Al-Saad S, Al-Shibli K, Donnem T, Persson M, Bremnes RM, Busund LT. The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br J Cancer 2008; 99: 1476-83.
9. Chen X, Ding J, Gao W, Yi X, Wang H, Li H. Expression of E-cadherin in non-small cell lung cancer: correlation with lymphatic metastasis and prognosis. Zhongguo Fei Ai Za Zhi 2002; 5: 260-2.
10. Tang X, Zhou Q, Zhang S, Liu L, Cheng N. A study on the relationship between E-cadherin, β-catenin expression and metastasis and prognosis in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002; 5: 263-7.
11. Shi R, Zhang D, Fang X, Yu J, Qiu X, Wang E. Expression of integrin-linked kinase and E-cadherin in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2005; 8: 291-6.
12. Choi YS, Shim YM, Kim SH, Son DS, Lee HS, Kim GY, Han J, Kim J. Prognostic significance of E-cadherin and beta-catenin in resected stage I non-small cell lung cancer. Eur J Cardiothorac Surg 2003; 24: 441-9.
13. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, Sugimachi K. Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 2000; 6: 4789-96.
14. Lin Q, Li M, Shen ZY, Xiong LW, Pan XF, Gen JF, Bao GL, Sha HF, Feng JX, Ji CY, Chen M. Prognostic impact of vascular endothelial growth factor-A and E-cadherin expression in completely resected pathologic stage I non-small cell lung cancer. Jpn J Clin Oncol 2010; 40: 670-6.
15. Liu D, Huang C, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Yokomise H. E-cadherin expression associated with differentiation and prognosis in patients with non-small cell lung cancer. Ann Thorac Surg 2001; 71: 949-54.
16. Nozawa N, Hashimoto S, Nakashima Y, Matsuo Y, Koga T, Sugio K, Niho Y, Harada M, Sueishi K. Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. Pathol Res Pract 2006; 202: 639-50.
17. Qiao GB, Wu YL, Ou W, Yang XN, Zhong WZ, Lin JY, Zhao J, Xie D, Guan XY. Expressions of E-cadherin in non-small cell lung cancer and it correlation with prognosis. Zhonghua Wai Ke Za Zhi 2005; 43: 913-7.
18. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 1998; 157: 1319-23.
19. Ucvet A, Kul C, Gursoy S, Erbaycu AE, Kaya SO, Dinc ZA, Yucel N. Prognostic value of epithelial growth factor receptor, vascular endothelial growth factor, E-cadherin, and p120 catenin in resected non-small cell lung carcinoma. Arch Bronconeumol 2011; 47: 397-402.
20. Yan H, Jiang Y, Zhang H, Chen X, Ma Y, Wang C. Expression of E-cadherin and β-catenin and their significance in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2005; 8: 202-6.
21. Zhang H, Liu J, Yue D, Gao L, Wang D, Zhang H, Wang C. Clinical significance of E-cadherin, β-catenin, vimentin and S100A4 expression in completely resected squamous cell lung carcinoma. J Clin Pathol 2013; 66: 937-45.
22. Stoops SL, Pearson AS, Weaver C, Waterson AG, Days E, Farmer C, Brady S, Weaver CD, Beauchamp RD, Lindsley CW. Identification and optimization of small molecules that restore E-cadherin expression and reduce invasion in colorectal carcinoma cells. ACS Chem Biol 2011; 6: 452-65.
23. Logan PC, Mitchell MD, Lobie PE. DNA methyltransferases and TETs in the regulation of differentiation and invasiveness of extra-villous trophoblasts. Front Genet 2013; 4: 265.
24. Simões-Correia J, Silva DI, Melo S, Figueiredo J, Caldeira J, Pinto MT, Girão H, Pereira P, Seruca R. DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo. Hum Mol Genet 2014; 23: 2094-105.
25. Simões-Correia J, Silva DI, Melo S, Figueiredo J, Caldeira J, Pinto MT, Girão H, Pereira P, Seruca R. DNAJB4 molecular chaperone distinguishes WT from mutant E-cadherin, determining their fate in vitro and in vivo. Hum Mol Genet 2014; 23: 2094-105.
26. Miao Y, Wang L, Zhang X, Xu X, Jiang G, Fan C, Liu Y, Lin X, Yu J, Zhang Y, Wang E. Promoter Methylation-Mediated Silencing of β-Catenin Enhances Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse Prognosis. PLoS One 2014; 9: e112258.
27. Fan C, Miao Y, Zhang X, Liu D, Jiang G, Lin X, Han Q, Luan L, Xu Z, Wang E. Btbd7 contributes to reduced E-cadherin expression and predicts poor prognosis in non-small cell lung cancer. BMC Cancer 2014; 14: 704.
28. Dong S, Zhao J, Wei J, Bowser RK, Khoo A, Liu Z, Luketich JD, Pennathur A, Ma H, Zhao Y. F-box protein complex FBXL19 regulates TGFβ1-induced E-cadherin down-regulation by mediating Rac3 ubiquitination and degradation. Mol Cancer 2014; 13: 76.
29. Sulzer MA, Leers MP, van Noord JA, Bollen EC, Theunissen PH. Reduced E-cadherin expression is associated with increased lymph node metastasis and unfavorable prognosis in non-small cell lung cancer. Am J Respir Crit Care Med 1998; 157: 1319-23.
30. Böhm M, Totzeck B, Birchmeier W, Wieland I. Differences of E-cadherin expression levels and patterns in primary and metastatic human lung cancer. Clin Exp Metastasis 1994; 12: 55-62.